DRI Healthcare Trust Closes Previously Announced Refinancing Of Preferred Securities

– Transaction significantly reduces potential dilution with a net reduction of warrants equivalent to 8.2% of units outstanding –

TORONTO, April 23, 2024 /CNW/ - DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (the "Trust") announces the closing of its previously announced preferred securities refinancing, whereby its US$114,760,000 aggregate principal amount of Series A and Series B preferred securities and 6,369,180 warrants were exchanged for US$135,202,000 aggregate principal amount of new Series C preferred securities and 1,749,996 new warrants. The new warrants have an exercise price of US$15.00, representing a 20% premium to the five day volume-weighted average price of the Trust's units.

"We will continue to seek to optimize our capital structure to lower our cost of capital," said Behzad Khosrowshahi, Chief Executive Officer of the Trust. "We have addressed potential dilution concerns by retiring approximately 6.4 million in-the-money warrants and replacing them with approximately 1.7 million out-of-the-money warrants. The transaction did not involve any cash out from the Trust and our fully diluted share count is reduced by 4.6 million, or 8.2% of units outstanding, following the transaction."

Scotia Capital Inc. acted as exclusive financial advisor to the Trust.

About DRI Healthcare Trust

DRI Healthcare Trust is managed by DRI Capital Inc. ("DRI Healthcare"), the pioneer in global pharmaceutical royalty monetization with a 35-year history of accelerating innovation by providing capital to inventors, academic institutions and biopharma companies. Since its founding in 1989, DRI Healthcare has deployed more than US$3.0 billion, acquiring more than 70 royalties on 45-plus drugs, including Eylea, Keytruda, Orserdu, Spinraza, Stelara, Vonjo, Zejula and Zytiga. DRI Healthcare Trust's units are listed and trade on the Toronto Stock Exchange in Canadian dollars under the symbol "DHT.UN" and in U.S. dollars under the symbol "DHT.U". To learn more, visit drihealthcare.com or follow us on LinkedIn.

SOURCE DRI Healthcare Trust

First published on Wed, Apr 24, 2024

Enjoyed what you read? Great news – there’s a lot more to explore!

Dive into our content repository of the latest tech news, a diverse range of articles spanning introductory guides, product reviews, trends and more, along with engaging interviews, up-to-date AI blogs and hilarious tech memes!

Also explore our collection of branded insights via informative white papers, enlightening case studies, in-depth reports, educational videos and exciting events and webinars from leading global brands.

Head to the TechDogs homepage to Know Your World of technology today!

Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. While we aim to provide valuable and helpful information, some content on TechDogs' site may not have been thoroughly reviewed for every detail or aspect. We encourage users to verify any information independently where necessary.

Tags:

DRI Healthcare Trust Pharmaceutical Keytruda Orserdu Spinraza Stelara Vonjo Zejula

Join The Discussion

Arctiq Acquires Shadow-Soft To Expand Observability And Automation Expertise

Compal Introduces High-Density NVIDIA HGX Rubin NVL8 Integrated Solution At GTC 2026

Niche Launches College Financial Aid Comparison Tool To Help Families Decode And Compare Offers

Shoplazza Adopts Agentic Commerce Architecture To Power AI-Driven E-Commerce Operations

Tata Communications Receives Frost & Sullivan's 2025 Global Company Of The Year Recognition For Leadership In Video-Managed Services